Simulations Plus has entered a definitive agreement to be acquired by affiliates of Altaris in an all-cash transaction valued at $375 million. This acquisition marks a significant move in the pharmaceutical industry, as Simulations Plus is known for its innovative software solutions that enhance drug development processes.
The deal highlights Altaris’ strategic focus on expanding its portfolio in the life sciences sector, particularly in areas that leverage advanced modeling and simulation technologies. By integrating Simulations Plus’ capabilities, Altaris aims to strengthen its position in the market and provide enhanced value to its clients through improved efficiency and reduced costs in drug development.
This acquisition could have broader implications for the industry, as it underscores the increasing importance of digital tools in pharmaceutical research and development. As companies seek to streamline operations and accelerate time-to-market, investments in technology-driven solutions like those offered by Simulations Plus are likely to gain traction.
Start your 7-day trial and see what the database can do →
